Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 BRL | -10.76% | -17.15% | -34.72% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-34.72% | 1.06B | C+ | ||
+0.75% | 99.96B | B- | ||
+22.40% | 87.73B | C+ | ||
+10.63% | 29.33B | C+ | ||
-4.40% | 18.21B | B | ||
-3.59% | 14.51B | A- | ||
+19.34% | 12.22B | B- | ||
+31.08% | 12B | B- | ||
+0.07% | 11.94B | A- | ||
-11.89% | 11.63B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Diagnosticos da América S.A. - Sao Paulo
- Ratings Diagnosticos da América S.A.